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Abstract Tyrosine kinases belonging to the discoidin domain
receptor (DDR) family are activated upon stimulation with
various types of collagen. In response to collagen treatment,
immunoprecipitation of DDR1 with an antibody specific to the
juxtamembrane region results in co-purification of a previously
unrecognized tyrosine phosphorylated protein of 62 kDa
molecular weight. Here, this protein is identified as C-terminal
cleavage product of the full-length DDR1 receptor and a DDR1-
specific shedding enzyme postulated. Shedding of DDR1 can be
partially blocked by the furin inhibitor decanoyl-RVKR-chlo-
romethylketone and completely inhibited by the hydroxamate-
based inhibitor batimastat. The characteristic of the DDR1
sheddase to be blocked by batimastat suggests that it belongs to
the membrane-bound matrix metalloproteinase or disintegrin and
metalloproteinase family of proteases. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Communication between cells amongst each other or be-
tween cells and the surrounding extracellular matrix is a
highly regulated process. A great diversity of cell surface re-
ceptors perceive signals from the outside, transmit them
through the plasma membrane and initiate downstream sig-
naling cascades. Many cytokines and growth factors are syn-
thesized as membrane-bound precursors and are released and
activated upon proteolysis. In turn, ligand binding and signal-
ing of many cell surface receptors is also regulated by proteol-
ysis. A large number of enzymes have been shown to function
as cell surface proteases, collectively termed sheddases, met-
zincins, secretases or convertases [1^3]. Sheddases are trans-
membrane metalloproteases with a Zn2 ion mediating catal-
ysis. They usually belong either to the family of membrane-
type matrix metalloproteases (MT-MMP) or to the ADAM (a
disintegrin and metalloprotease) family.
The diversity of sheddase activity is paralleled by the diver-
sity of their substrates. Well characterized substrates for shed-
dases are cell adhesion receptors, such as VCAM-1, L-selectin,
and syndecan, G protein-coupled receptors, such as the V2
vasopressin receptor, or membrane-anchored precursors of
receptor ligands, such as transforming growth factor-K
(TGF-K), tumor necrosis factor-K (TNF-K), Kit ligand and
Fas ligand. Much attention has recently also been given to
the inappropriate shedding of the L-amyloid precursor protein
thereby causing Alzheimer’s disease [4]. Clearly, sheddases
have a rather wide substrate speci¢city, which is exempli¢ed
by TACE (ADAM17) [5]. Originally, TACE was identi¢ed as
TNF-K processing enzyme, but it has now been shown to also
cleave colony-stimulating factor receptor, AAP, HER4, neu-
regulin, L-selectin, fractalkine and Notch [6^12]. The TACE-
related protease ADAM10 has been implicated in shedding of
the L1 adhesion molecule [13]. The shedding of cell surface
receptors can be either constitutive or induced by antibodies
and other stimuli [14]. Ectodomain shedding of receptor tyro-
sine kinases (RTK) is reported for the epidermal growth fac-
tor (EGF) receptor, HER2 receptor, platelet-derived growth
factor receptor, the basic ¢broblast growth factor receptor,
the nerve growth factor receptor, insulin-like growth factor
receptor and the hepatocyte growth factor receptor (c-Met)
[15^17]. Several stimuli trigger the shedding of RTK, such
as the activation of protein kinase C by phorbol esters. Li-
gand-induced shedding has been reported for the RTK TrkA
upon stimulation with nerve growth factor [18]. Furthermore,
the EGF receptor uses the Erk and p38 mitogen-activated
protein kinase pathway to trigger ectodomain shedding of
TGF-K, TNF-K and L-selectin [19]. Some of the sheddases
are initially generated as precursors and are activated by
intracellular serine endoproteases of the furin family [10].
Various compounds e¡ectively inhibit sheddases, including
Zn-chelating agents like EDTA. Most of the more speci¢c
sheddase inhibitors are hydroxamate derivatives and have
been shown to block matrix metalloproteinases as well [20].
Several of these inhibitors have entered clinical trials due to
potent anti-metastatic or anti-angiogenic properties.
Discoidin domain receptors 1 and 2 (DDR1 and DDR2)
are a subfamily of the RTK class showing distinct structural
and functional homologies. In their extracellular region both
receptors have an N-terminal domain homologous to the Dic-
tyostelium discoideum protein discoidin I [21]. A functional
homology between DDR1 and DDR2 is given by the fact
that both receptors are activated by collagen. Whereas
DDR1 activation is achieved by type I to type VI and type
VIII collagens, DDR2 is only activated by ¢brillar collagens
[22,23]. The 160 amino acid long discoidin domain is followed
by an approx. 200 amino acid long stalk region. Whereas the
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discoidin domain is essential for collagen binding of DDR1,
both domains are necessary for receptor signaling [24]. Max-
imal DDR1 phosphorylation is reached after several hours in
adherent cells, but much faster in suspension [23,25].
The cDNA encoding human DDR1 has been cloned from
several tissues or carcinoma cells [26,27]. Expression of DDR1
is predominantly seen in epithelial cells, particularly from kid-
ney, lung, gastrointestinal tract, and brain, but also in corneal
and dermal ¢broblasts [26,28^30]. Up-regulated DDR1 ex-
pression has been reported from breast, ovarian, esophagus
and brain tumors [31^35].
Thus far, ¢ve isoforms of DDR1 (indicated with the a⁄xes
a^e) have been cloned as a result of alternative splicing [36].
Compared to the longest c-isoform, the b-isoform lacks six
amino acids inserted in the kinase domain between exons 13
and 14 [26]. The a-, d- and e-isoforms arise through alterna-
tive splicing in the juxtamembrane region. The deletion of
exon 11 encoding 37 amino acids gives rise to DDR1a, the
deletion of exons 11 and 12 results in DDR1d. In DDR1e, the
¢rst half of exon 10 and all of exons 11 and 12 are missing
[36]. Whereas DDR1a retains the reading frame and is there-
fore an active kinase, the coding sequence of DDR1d and
DDR1e goes out of frame and renders both isoforms ki-
nase-dead. Deletion of DDR1 in the mouse germ line resulted
in viable animals, which are signi¢cantly smaller than their
littermates [37]. Female DDR1-null mice show defects in blas-
tocyst implantation and mammary gland development. Fur-
thermore, in primary vascular smooth muscle cells cultivated
from DDR1-null mice decreased proliferation, collagen at-
tachment and migration have been observed [38].
Here, we provide evidence that activation of DDR1 led to
enhanced activity of a cell surface protease, which cleaves
DDR1 in a region proximal to the membrane. Due to the
sensitivity towards batimastat, we propose that an ADAM-
or MT-MMP-related metalloproteinase is responsible for
DDR1 shedding.
2. Materials and methods
2.1. Cell lines, antibodies and other reagents
Human mammary carcinoma T-47D cells were obtained from
American Type Tissue Culture Collection and cultivated under rec-
ommended conditions. The generation of mouse ¢broblast NIH3T3
cells stably expressing DDR1b has been described earlier [26]. Rat
type I collagen was purchased from Collaborative Biomedical Prod-
ucts (Bedford, MA, USA). Decanoyl-RVKR-chloromethylketone was
from Bachem (Heidelberg, Germany) and batimastat from British
Biotech. Polyclonal antibodies to DDR1 were raised against a peptide
corresponding to amino acids 505^523 of DDR1b [23]. An antibody
against the C-terminus of DDR1 was obtained from Santa Cruz Bio-
technology (Santa Cruz, CA, USA, amino acids 894^913). Monoclo-
nal anti-phosphotyrosine antibody 4G10 was from Upstate Biotech-
nology (Lake Placid, NY, USA).
2.2. Immunoprecipitation and Western blot analysis
Semi-con£uent T-47D cells were stimulated with 10 Wg/ml collagen
and lysed with 1% Triton X-100, 0.1% sodium dodecyl sulfate (SDS),
150 mM NaCl, 5 mM EDTA, 50 mM Tris^HCl (pH 7.5), 10 mM
NaF, 1 mM phenylmethylsulfonyl £uoride, 1 mM sodium orthovana-
date, 10 Wg/ml aprotinin. The cellular lysates were centrifuged at 4‡C
and 13 000 rpm for 10 min. Equal amounts of protein were subjected
to anti-DDR1 immunoprecipitation. Following SDS-polyacrylamide
gel electrophoresis, proteins were transferred to a nitrocellulose mem-
brane (Schleicher and Schuell) and immunoblotted with antibodies
diluted 1:1000 (4G10) and 1:500 (DDR1) in 50 mM Tris^HCl (pH
7.5), 150 mM NaCl, 5 mM EDTA, 0.5% gelatin overnight. Western
blots were incubated with mouse or rabbit peroxidase-coupled second-
ary antibodies (Bio-Rad) and developed with enhanced chemilumines-
cence (Amersham). Before reprobing, the membrane was stripped in
70 mM Tris^HCl (pH 6.8), 2% SDS, 0.1% L-mercaptoethanol at 50‡C
for 15 min.
2.3. Scanning densitometry
Western blot results were quanti¢ed by scanning densitometry using
the Quantity-One software (Bio-Rad, Munich, Germany).
3. Results
3.1. Copuri¢cation of a 62 kDa protein from DDR1
immunoprecipitation
In our previous work, we identi¢ed endogenous expression
of DDR1 in many carcinoma cell lines, including the human
mammary carcinoma cell line T-47D [26]. Overnight stimula-
tion of T-47D cells with 10 Wg/ml type I collagen resulted in
sustained tyrosine phosphorylation of DDR1 [23]. In this
study, we performed a time course experiment and stimulated
T-47D cells with collagen for 20 min, 2 h and 18 h. Cell
lysates were subjected to immunoprecipitation using an anti-
body directed against the juxtamembrane region of DDR1b,
which is the isoform predominantly expressed in T-47D cells.
Western blot analysis with an anti-phosphotyrosine antibody
detected an increase in DDR1 phosphorylation concomitant
with the duration of collagen stimulation (Fig. 1A). Addition-
ally, three other tyrosine-phosphorylated bands of approxi-
mately 120, 105 and 62 kDa coprecipitated with DDR1.
Whereas phosphorylation of the 120 and 105 kDa protein
was already detected in untreated cells and did not chance
upon collagen treatment, phosphorylation of the 62 kDa in-
creased during the time period studied. The 62 kDa band was
clearly distinct from the immunoglobulin heavy chain running
at 50^58 kDa. Quanti¢cation of the Western blot by scanning
Fig. 1. Collagen-induced processing of DDR1 depends on tyrosine
kinase autophosphorylation. A: Human mammary carcinoma T-
47D cells were stimulated with collagen for various periods of time.
Cell lysates were analyzed by anti-DDR1 immunoprecipitation fol-
lowed by anti-phosphotyrosine Western blotting. A tyrosine-phos-
phorylated 62 kDa protein is detected after 2 and 18 h stimulation
with collagen. Molecular weight markers are indicated. B: The in-
tensity of DDR1 (open bars) and 62 kDa (checked bars) tyrosine
phosphorylation is measured by densitometry. The relative amounts
of phosphorylated 62 kDa protein compared to DDR1 are given in
percent.
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densitometry revealed that phosphorylation of the 62 kDa
protein was signi¢cantly delayed compared to the phosphor-
ylation of DDR1 (Fig. 1B).
3.2. Sustained phosphorylation of 62 kDa protein
Next, we extended the time course of DDR1 activation for
several days. T-47D cells were stimulated with collagen and
left without further treatment for up to 4 days. Immunopre-
cipitation and Western blot analysis indicated that DDR1
remains tyrosine-phosphorylated for up to 4 days upon colla-
gen activation (Fig. 2). Again, two proteins with molecular
weights of 105 and 120 kDa coprecipitated with unstimulated
DDR1 and remained unchanged upon collagen activation. In
contrast, phosphorylation of the 62 kDa protein was not seen
in unstimulated cells and only appeared upon collagen treat-
ment. At day 4, an additional band of 58 kDa molecular
weight was visible. Upon longer exposure of this Western
blot, the intensities of phosphorylation for DDR1b and the
62 kDa protein were equally strong compared to the signals
seen in Fig. 1 (data not shown).
3.3. The 62 kDa protein is a C-terminal fragment of DDR1
In order to identify the 62 kDa protein, we reasoned that it
could be either a substrate of DDR1 that is tyrosine-phos-
phorylated upon receptor activation and coprecipitates with
the receptor, or it could be a cleavage product of the receptor
itself. To test the latter possibility, we treated T-47D cells with
collagen overnight. The lysates were subjected to immunopre-
cipitation with a DDR1-speci¢c antibody as before. Now,
however, we not only analyzed the immunoprecipitates by
anti-phosphotyrosine Western blotting, but used an antibody
speci¢c for the C-terminus of DDR1 (Fig. 3A,B). Indeed, the
tyrosine-phosphorylated 62 kDa protein was recognized by
the anti-DDR1 antibody, indicating that DDR1 is proteolyti-
cally processed in response to ligand activation. Because the
antisera for immunoprecipitation and Western blotting were
both from the same species in this experiment, the 62 kDa
band is detected by the anti-DDR1 antibody with somewhat
weaker intensity compared to the anti-phosphotyrosine West-
ern blot. However, the 62 kDa protein was always clearly
separated from the immunoglobulin heavy chain (arrow in
Fig. 3B).
To demonstrate that DDR1 shedding is not restricted to
T-47D cells, we used mouse ¢broblast NIH3T3 cells, which
had been previously transfected with the full-length DDR1b
cDNA [26]. Cells were stimulated with collagen and lysates
subjected to anti-DDR1 immunoprecipitation followed by
anti-phosphotyrosine Western blotting (Fig. 3C). We detected
the 125 kDa DDR1 precursor protein together with the 62
kDa protein also in NIH3T3 cells. Upon reprobing the blot
with the anti-DDR1 antibody, we con¢rmed the identity of
the 62 kDa protein as a C-terminal cleavage fragment of
DDR1 (Fig. 3D).
Fig. 2. Sustained presence of DDR1 L-subunit after collagen activa-
tion. T-47D cells were stimulated with collagen for up to 4 days.
Cell lysates were analyzed by anti-DDR1 immunoprecipitation fol-
lowed by anti-phosphotyrosine Western blotting. A continuous in-
crease in phosphorylation of the 62 kDa protein is detected through
the time period studied. Additionally, a 58 kDa protein is detected
after 4 days of stimulation.
Fig. 3. Processing of DDR1 in response to collagen stimulation.
T-47D cells (A,B) and NIH3T3 DDR1b cells (C,D) were stimulated
with collagen overnight. Cells lysates were subjected to immunopre-
cipitation with a DDR1-speci¢c antibody. Bound material was ana-
lyzed by Western blotting using an antibody directed against phos-
photyrosine (A,C) and reprobed with anti-DDR1 antibody (B,D).
The 62 kDa protein (indicated by arrows) is identi¢ed as a cleavage
product of DDR1 (L-subunit).
Fig. 4. Furin inhibitor reduces shedding of DDR1. A: T-47D cells
were stimulated overnight with collagen in the presence or absence
of decanoyl-RVKR-chloromethylketone. Cell lysates were analyzed
by anti-DDR1 immunoprecipitation followed by anti-DDR1 West-
ern blotting. A reduction in ligand-induced DDR1 shedding is ob-
served in the presence of the furin inhibitor. B: The intensities of
the DDR1 (open bars) and L-subunit (checked bars) signal are mea-
sured by densitometry. The percentage of L-subunit compared to
unprocessed DDR1 is given.
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3.4. DDR1 is shed by a furin-like activity
Shedding of a DDR-related RTK, the c-Met receptor, was
shown to be achieved by furin cleavage [39]. We therefore
wanted to test if DDR1 is also processed by furins. T-47D
cells were treated with collagen overnight in the presence or
absence of the furin inhibitor decanoyl-RVKR-chloromethyl-
ketone at 100 WM concentration. Immunoprecipitation of
DDR1 showed that the sheddase activity is partially blocked
by the inhibitor (Fig. 4). However, only about 50% reduction
of ligand-induced shedding was observed, whereas the inhib-
itor enhanced the constitutive level of processing seen in un-
stimulated cells.
3.5. Complete inhibition of DDR1 shedding by batimastat
Since DDR1 processing is only partially inhibited by deca-
noyl-RVKR-chloromethylketone, we tested batimastat, a hy-
droxamate-derived inhibitor speci¢c for metzincins. T-47D
cells were stimulated with collagen overnight in the absence
or presence of 10 Wg/ml batimastat. DDR1 phosphorylation
was detected by Western blot analysis and expression of
DDR1 by reprobing with a receptor-speci¢c antibody (Fig.
5). In the presence of batimastat, DDR1 processing was com-
pletely abolished which strongly indicates that ligand-induced
DDR1 processing is mediated by a sheddase. Again, due to
the conditions used for Western blotting the detection of the
62 kDa protein with the antibody against phosphotyrosine
resulted in much stronger signals than with the anti-DDR1
antibody.
4. Discussion
Ectodomain shedding provides crucial mechanisms regulat-
ing the signaling capacity of cell surface receptors. On one
hand, ligands can be synthesized as transmembrane pro-
forms, inactively sequestered in the tissue and converted to
an active form only by shedding. On the other hand, cleaving
the ligand binding domain can terminate receptor signaling.
Here we found that DDR1 is expressed in mammary carcino-
ma cells as a 125 kDa full-length receptor and, upon collagen
ligand engagement, is tyrosine-phosphorylated and proteolyti-
cally processed. We showed that the kinetic of DDR1 cleav-
age was even more protracted than the process of activation.
Whereas collagen stimulation for 2 h resulted in more than
80% maximal DDR1 tyrosine phosphorylation, just 6% of the
full-length receptor underwent shedding. Only after 18 h of
collagen stimulation was 55% of the receptor processed into a
62 kDa membrane-anchored L-subunit (Fig. 1B). Collagen
treatment for 4 days resulted in a further increase in process-
ing. A 58 kDa protein was detected together with the 62 kDa
L-subunit suggesting that DDR1 shedding was a stepwise pro-
cess and sequentially happened at two distinct sites. Alterna-
tively, the 62 kDa protein was converted into the 58 kDa
protein by intracellular modi¢cation. Taking the molecular
size of the L-subunit into account, we calculated that process-
ing of DDR1 took place proximal to the membrane. Mem-
brane-proximal shedding involving residues 10^15 amino
acids distal from the transmembrane region has been reported
for TNF-K, L-selectin, interleukin-6 receptor and fractalkine
[1,9]. However, swapping experiments between di¡erent recep-
tors indicated that sheddases have a relaxed speci¢city for
their cleavage sites [7]. As DDR1 cleavage is inhibited by
batimastat, an enzyme of the family of MT-MMP or
ADAM is most likely involved in DDR1 shedding. Experi-
ments are under way addressing the nature of the shedding
enzyme by using cells from knockout mice or inhibitors selec-
tive for individual sheddases.
Interestingly, human DDR1 displays the sequence RFRR
(amino acids 304^307) in the stalk region, a sequence comply-
ing with the consensus site for furin endoproteases. However,
the data presented here suggest that this site is not involved in
ligand-induced DDR1 shedding. First, furin-like endopepti-
dases are localized in the trans-Golgi network and act during
the maturation of membrane-anchored proteins, whereas
DDR1 processing takes place in the extracellular space after
contacting collagen. Secondly, point mutations switching one
or several of the arginines in the recognition sequence to ala-
nine did not in£uence DDR1 shedding (data not shown).
Lastly, while DDR1 sequences from other species have a
highly related overall sequence, the RFRR motif is not con-
served. Between the DDR1 sequences from human and Cae-
norhabditis elegans, only phenylalanine is conserved in the
recognition motif [40]. Although the furin inhibitor decano-
yl-RVKR-chloromethylketone partially blocks DDR1 shed-
ding, it may not act on the DDR1 sheddase directly but in-
hibits the maturation of the ADAM or MT-MMP family
member that acts as a DDR1 sheddase. This hypothesis is
supported by the observation that the activation of MT5-
MMP and ADAM-TS12 takes places by furin-mediated pro-
domain cleavage and is blocked by decanoyl-RVKR-chloro-
methylketone [41,42]. So far, we are unable to give a satisfac-
tory explanation for the result showing that DDR1 shedding
is also induced by decanoyl-RVKR-chloromethylketone in the
absence of ligand.
Several possible mechanisms for the ligand-induced shed-
ding of DDR1 can be proposed, suggesting either a direct
or an indirect mode of action (Fig. 6). Three potential mech-
anisms are proposed here. (i) Collagen binding to the discoi-
din domain of DDR1 and receptor dimerization may induce
changes in the conformation of the stalk region particular of
the sequence close to the plasma membrane. These conforma-
tional changes could open up a sheddase recognition site. The
sheddase would already be present at the membrane in close
vicinity to the receptor. (ii) Ligand-induced tyrosine phos-
Fig. 5. Batimastat completely blocks DDR1 shedding. T-47D cells
were stimulated with collagen in the presence or absence of batima-
stat. Cell lysates were subjected to anti-DDR1 immunoprecipitation
and analyzed by anti-phosphotyrosine Western blotting followed by
anti-DDR1 Western blotting. Note the complete absence of DDR1
shedding in the presence of batimastat.
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phorylation of DDR1 may induce clustering of a variety of
sca¡olding and signaling molecules. Amongst others, protein^
protein interactions would take place involving phosphorylat-
ed tyrosines in the cytoplasmic domain of DDR1 and SH2 or
PTB domain containing proteins. These interacting proteins
could simultaneously recruit a sheddase molecule and bring it
proximal to the receptor. DDR1 is recognized as substrate
and cleaved by the sheddase. (iii) Prolonged activation of
DDR2 has been shown to result in up-regulation of MMP1
[23]. Therefore, activation of DDR1 may also result in tran-
scriptional up-regulation of proteases. This up-regulation
could include a sheddase that cleaves the receptor itself. Addi-
tionally more complex mechanisms of protease activation,
such as pro-enzyme cleavage or alleviation of inhibitors,
may also be considered.
Why do mammary carcinoma cells shed DDR1 in a ligand-
dependent manner? We recently showed that cells derived
from DDR1-null mice have severely impaired adhesion to
collagen and migration on collagen [38]. In a growing mam-
mary tumor, DDR1 may be essential for the initial attach-
ment of invasive cells to the basement membrane collagen.
Following DDR1 activation, the cell/matrix contact is termi-
nated by ectodomain shedding, allowing further migration of
the cell. Since the L-subunit of DDR1 is still tyrosine-phos-
phorylated following processing, the proliferative pathways
initially triggered by the full-length receptor remain active.
Currently, we can only speculate on the functional role of
the ectodomain of DDR1. The ectodomain potentially re-
mains attached to the collagen and blocks further interaction
of collagen with full-length signalling-competent receptors.
Alternatively, DDR1 ectodomain is transported through
body £uids and functions as signalling molecule by binding
to molecules other than collagen acting on cells distant from
DDR1-expressing cells. More work will be necessary to gain
further insight into these mechanisms.
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